SCHEMBL24758648

SCHEMBL24758648

CC(=O)c1ccc2onc(C)c2c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.49
KDM4E B2RXH2 4/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
BRD4 O60885 2/20 0.49
BRD2 P25440 1/20 0.48
CREBBP Q92793 1/20 0.48
MAPK14 Q16539 1/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
NPC1 O15118 3/20 0.46
RAB9A P51151 2/20 0.46
GAA P10253 2/20 0.46
HTT P42858 1/20 0.46
HIF1A Q16665 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
MAPT P10636 1/20 0.42
MAPK10 P53779 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30845314 1.00 ALDH1A1 (0.49) ALDH1A1KDM4EL3MBTL1BRD4BRD2
SCHEMBL5917986 0.86 MAPK14 (0.50) ALDH1A1KDM4EL3MBTL1BRD4MAPK14
SCHEMBL15660075 0.82 CA12 (0.49) ALDH1A1KDM4EBRD4CREBBPMAPK14
SCHEMBL30040356 0.82 CA12 (0.49) ALDH1A1KDM4EBRD4CREBBPMAPK14
SCHEMBL17307543 0.79 CA12 (0.48) ALDH1A1KDM4EMAPK14KMT2AMEN1
SCHEMBL28554333 0.76 NPC1 (0.48) ALDH1A1KDM4ENPC1RAB9AGAA
SCHEMBL15660776 0.75 MAPK14 (0.45) ALDH1A1KDM4EL3MBTL1BRD4MAPK14
SCHEMBL25303944 0.74 CYP1B1 (0.54) ALDH1A1KMT2AMEN1NPC1RAB9A
SCHEMBL2303791 0.74 ESR1 (0.59)
SCHEMBL5985206 0.74 MAPT (0.53) BRD4MAPK14NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067641-A1 INHIBITORS OF TRIM33 AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-02-29 US disclosed
US-11731967-B2 Inhibitors of TRIM33 and methods of use DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-08-22 US disclosed
WO-2022263548-A1 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS LEAD DISCOVERY CENTER GMBH (DE) 2022-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731967-B2 Inhibitors of TRIM33 and methods of use TRIM33, TRIM28, TRIM4 ALDH1A1 3246/4885KDM4E 1284/4885L3MBTL1 487/4885
US-20240067641-A1 INHIBITORS OF TRIM33 AND METHODS OF USE TRIM33, TRIM28, TRIM4 ALDH1A1 3246/4885KDM4E 1284/4885L3MBTL1 487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.